Patents by Inventor Suayib YALCIN

Suayib YALCIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

TREATMENT OF PATIENTS DIAGNOSED WITH PANCREATIC DUCTAL ADENOCARCINOMA USING USING MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)

Publication number: 20180221478

Abstract: The present disclosure relates to the field of immunotherapy of cancer, in particular pancreatic ductal adenocarcinoma (PDAC). Means and methods for treatment of a population of PDAC patients suffering from PDAC tumours which express wildtype KRAS, HRAS or NRAS are disclosed. The claimed antibody is Nimotuzumab. The pancreatic cancer preferably does not contain KRAS mutations at position 12, 16, 61, 154.

Type: Application

Filed: July 27, 2016

Publication date: August 9, 2018

Applicants: INNOCIMAB PTE LTD, ONCOSCIENCE AG

Inventors: Dirk STRUMBERG, Beate SCHULTHEIS, Matthias P. EBERT, Jens SIVEKE, Andrea KERKHOFF, Ralf HOFHEINZ, Dirk M. BEHRINGER, Wolfgang E. SCHMIDT, Erdem GOKER, Sara DE DOSSO, Michael KNEBA, Suayib YALCIN, Friedrich OVERKAMP, Frank SCHLEGEL, Markus DOMMACH, Robert ROHRBERG, Tilman STEINMETZ, Ferdinand BACH, Dirk REUTER, Rikrik Asiyah ILYAS, Normando E. IZNAGA ESCOBAR

TREATMENT OF PATIENTS DIAGNOSED WITH PANCREATIC DUCTAL ADENOCARCINOMA USING USING MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)